Undisclosed FGFR2b-targeting ADC / Shanghai Ailux Biotechnology - LARVOL DELTA

Preclinical evaluation of a novel and highly differentiated FGFR2b-targeting ADC with low risk of ocular toxicity (AACR 2026) - "Bemarituzumab, an ADCC-enhanced FGFR2b antagonist, has demonstrated efficacy in patients with FGFR2b-overexpressing G/GEJ cancer. Together, these data demonstrate preclinical efficacy and low risk of ocular toxicity of a FGFR2-targeting ADC utilizing ALX007 as a highly differentiated antibody backbone. Further development for the treatment of FGFR2b-expressing tumors is warranted."

ADC • Preclinical • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor • FGF10 • FGF7 • FGFR2